首页> The Pediatric infectious disease journal> Pharmacokinetics, Safety, Tolerability and Antiviral Activity of Switching to Oral Rilpivirine in Combination With Other Antiretroviral Therapy in Virologically Suppressed Children Living With HIV-1 Infection: Forty-eight-week Results From the Phase 2, Open-label, Single-arm, PICTURE Study.

Pharmacokinetics, Safety, Tolerability and Antiviral Activity of Switching to Oral Rilpivirine in Combination With Other Antiretroviral Therapy in Virologically Suppressed Children Living With HIV-1 Infection: Forty-eight-week Results From the Phase 2, Open-label, Single-arm, PICTURE Study.

导出 LinkOut

翻译打印收藏纠错

第一作者： Johan,Lombaard

第一单位： From the Josha Research, Bloemfontein, South Africa.

作者： Johan,Lombaard ^[1] ; Francis,Ssali ^[2] ; Visal,Moolasart ^[3] ; Alfredo,Guarino ^[4] ; Raffaele,Badolato ^[5] ; Stefania,Bernardi ^[6] ; Margarida,Tavares ^[7] ; Claudia,Fortuny ^[8] ; Linda,Aurpibul ^[9] ; Supattra,Rungmaitree ^[10] ; Rodica,Van Solingen-Ristea ^[11] ; Veerle,Van Eygen ^[11] ; Sandy,Van Hemelryck ^[11] ; Alberto,Russu ^[12] ; Ken,Kurosawa ^[13] ; Minaka,Shibuya ^[13] ; Simon,Vanveggel ^[11] ; Erika,Van Landuyt ^[11]

作者单位： From the Josha Research, Bloemfontein, South Africa. ^[1] Joint Clinical Research Centre, Kampala, Uganda. ^[2] Bamrasnaradura Infectious Diseases Institute, Ministry of Public Health, Nonthaburi, Thailand. ^[3] Azienda Ospedaliera Universitaria Federico II, Napoli, Italy. ^[4] Istituto Molecolare Angelo Nocivelli dell'Universita' degli Studi di Brescia, ERN-RITA, ASST Spedali Civili di Brescia, Brescia, Italy. ^[5] IRCCS Ospedale Pediatrico Bambino Gesu, Rome, Italy. ^[6] CHSJ-Hosp. Sao Joao, Porto, Portugal. ^[7] Hosp. Sant Joan De Deu, Barcelona, Spain. ^[8] Research Institute for Health Sciences, Chiang Mai, Thailand. ^[9] Siriraj Hospital Mahidol University, Bangkok, Thailand. ^[10] Johnson & Johnson, Beerse, Belgium. ^[11] Johnson & Johnson, Milan, Italy. ^[12] Johnson & Johnson, Tokyo, Japan. ^[13]

关键词 HIV-1 antiretroviral therapy children pharmacokinetics rilpivirine safety